Haematologica (May 2025)
Improved outcomes of acute lymphoblastic leukemia after allogeneic blood or marrow transplantation with high-dose post-transplantation cyclophosphamide in the era of more effective pre-transplant therapy
- Jonathan A. Webster,
- Madison Reed,
- Hua-Ling Tsai,
- Philip H. Imus,
- Douglas B. Smith,
- Alexander J. Ambinder,
- Mark J. Levis,
- Amy E. DeZern,
- Gabrielle T. Prince,
- Tania Jain,
- Javier Bolaños-Meade,
- Lukasz P. Gondek,
- Gabriel Ghiaur,
- William Brian Dalton,
- Theodoros Karantanos,
- Suman Paul,
- Ephraim J. Fuchs,
- Cole Sterling,
- Lode J. Swinnen,
- Nina Wagner-Johnston,
- Richard F. Ambinder,
- Christian B. Gocke,
- Syed Abbas Ali,
- Carol Ann Huff,
- Leo Luznik,
- Ravi Varadhan,
- Richard J. Jones,
- Ivana Gojo
Affiliations
- Jonathan A. Webster
- Division of Hematologic Malignancy, Department of Oncology, Johns Hopkins University, Baltimore, MD
- Madison Reed
- Department of Internal Medicine, Yale University, New Heaven, CT
- Hua-Ling Tsai
- Division of Biostatistics and Bioinformatics, Department of Oncology, Johns Hopkins University, Baltimore, MD
- Philip H. Imus
- Division of Hematologic Malignancy, Department of Oncology, Johns Hopkins University, Baltimore, MD
- Douglas B. Smith
- Division of Hematologic Malignancy, Department of Oncology, Johns Hopkins University, Baltimore, MD
- Alexander J. Ambinder
- Division of Hematologic Malignancy, Department of Oncology, Johns Hopkins University, Baltimore, MD
- Mark J. Levis
- Division of Hematologic Malignancy, Department of Oncology, Johns Hopkins University, Baltimore, MD
- Amy E. DeZern
- Division of Hematologic Malignancy, Department of Oncology, Johns Hopkins University, Baltimore, MD
- Gabrielle T. Prince
- Division of Hematologic Malignancy, Department of Oncology, Johns Hopkins University, Baltimore, MD
- Tania Jain
- Division of Hematologic Malignancy, Department of Oncology, Johns Hopkins University, Baltimore, MD
- Javier Bolaños-Meade
- Division of Hematologic Malignancy, Department of Oncology, Johns Hopkins University, Baltimore, MD
- Lukasz P. Gondek
- Division of Hematologic Malignancy, Department of Oncology, Johns Hopkins University, Baltimore, MD
- Gabriel Ghiaur
- Division of Hematologic Malignancy, Department of Oncology, Johns Hopkins University, Baltimore, MD
- William Brian Dalton
- Division of Hematologic Malignancy, Department of Oncology, Johns Hopkins University, Baltimore, MD
- Theodoros Karantanos
- Division of Hematologic Malignancy, Department of Oncology, Johns Hopkins University, Baltimore, MD
- Suman Paul
- Division of Hematologic Malignancy, Department of Oncology, Johns Hopkins University, Baltimore, MD
- Ephraim J. Fuchs
- Division of Hematologic Malignancy, Department of Oncology, Johns Hopkins University, Baltimore, MD
- Cole Sterling
- Division of Hematologic Malignancy, Department of Oncology, Johns Hopkins University, Baltimore, MD
- Lode J. Swinnen
- Division of Hematologic Malignancy, Department of Oncology, Johns Hopkins University, Baltimore, MD
- Nina Wagner-Johnston
- Division of Hematologic Malignancy, Department of Oncology, Johns Hopkins University, Baltimore, MD
- Richard F. Ambinder
- Division of Hematologic Malignancy, Department of Oncology, Johns Hopkins University, Baltimore, MD
- Christian B. Gocke
- Division of Hematologic Malignancy, Department of Oncology, Johns Hopkins University, Baltimore, MD
- Syed Abbas Ali
- Division of Hematologic Malignancy, Department of Oncology, Johns Hopkins University, Baltimore, MD
- Carol Ann Huff
- Division of Hematologic Malignancy, Department of Oncology, Johns Hopkins University, Baltimore, MD
- Leo Luznik
- Division of Hematologic Malignancy, Department of Oncology, Johns Hopkins University, Baltimore, MD, USA; Section of Hematology/Oncology, Department of Medicine, Baylor College of Medicine, Houston, TX
- Ravi Varadhan
- Division of Biostatistics and Bioinformatics, Department of Oncology, Johns Hopkins University, Baltimore, MD
- Richard J. Jones
- Division of Hematologic Malignancy, Department of Oncology, Johns Hopkins University, Baltimore, MD
- Ivana Gojo
- Division of Hematologic Malignancy, Department of Oncology, Johns Hopkins University, Baltimore, MD
- DOI
- https://doi.org/10.3324/haematol.2025.287433
- Journal volume & issue
-
Vol. 999,
no. 1
Abstract
The therapeutic landscape in ALL has changed dramatically over the last decade. Allogeneic blood or marrow transplantation (AlloBMT) has also evolved and remains an important option for consolidation. We assessed the interplay between these factors by analyzing the outcomes of 251 adult ALL (214 B and 37 T ALL) patients undergoing alloBMT with post-transplantation cyclophosphamide (PTCy) across two eras: 2008-2014 (ERA1) and 2015-2022 (ERA2). ERA1 patients were younger (median age 45.5 vs. 50, p=0.03), less likely to have an HCT-CI ≥4 (9% vs. 21%, p=0.01), more likely to have MRD by flow cytometry (20% vs. 9%, p=0.01) and receive myeloablative conditioning (56% vs. 3%, p
